Web1 apr. 2024 · Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. For more information, please visit. www.sagerx.com . Forward-Looking Statements Web16 feb. 2024 · Sage Therapeutics, Inc. (NASDAQ:NASDAQ:SAGE) Q4 2024 Earnings Conference Call February 16, 2024 8:00 AM ETCompany ParticipantsHelen Rubinstein ... Jim Doherty. Absolutely, Barry.
Validation of a Suite of ERP and QEEG Biomarkers in a Pre …
Web15 sep. 2024 · SAGE-718, Sage’s first-in-class NMDA receptor PAM and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease (HD), Parkinson’s disease (PD) and Alzheimer’s disease (AD). WebSage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs. … texture screen
Sage Therapeutics Announces Presentation of Promising Results …
Web13 mei 2024 · Jim Doherty, Chief Research Officer, Sage Therapeutics Mike Quirk, Vice President, Pharmacology, Sage Therapeutics Aaron Koenig, Executive Medical Director, Early Development, Sage Therapeutics WebJIM DOHERTY, Ph.D. Chief Development Officer. Jim leads the Sage research team that has pioneered more decisive methods for making development decisions. He joined … Web16 sep. 2024 · Cecchi, Marco and Adachi, Megumi and Basile, Anthony and Buhl, Derek and Chadchankar, Heramb and Christensen, Søren and Christian, Edward and Doherty, Jim and Fadem, KC and Farley, Brandon and Forman, Mark and Honda, Sokichi and Johannesen, Jason and Kinon, Bruce and Klamer, Daniel and Michael, Marino and … texture san gach